Drug Approval Law Will Likely Deter Pharma Delay Tactics
Law360 (February 25, 2020, 3:52 PM EST) -- Pharmaceutical manufacturers have used many strategies to delay competition from lower-cost equivalent products over the years. While so-called pay-for-delay has garnered more media attention, manufacturers have also blocked competition by denying access to product samples needed for development of lower-cost equivalents.
But in late December, Congress enacted a law that seeks to prevent this practice. Tucked away in the 700-plus page omnibus Further Consolidated Appropriations Act is a bipartisan bill known as the Creating and Restoring Equal Access to Equivalent Samples, or CREATES, Act, H.R. 965/S. 340. Both sides of the political aisle will laud their party’s efforts in passing this...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!